BioMarin Pharmaceutical Inc. has appointed Arpit Davé as its new Chief Digital and Information Officer, tasked with enhancing the company’s technology strategy and digital transformation efforts.
BioMarin Pharmaceutical Inc., a prominent global biotechnology firm specializing in rare diseases, has announced the appointment of Arpit Davé as Executive Vice President and Chief Digital and Information Officer. This newly created position underscores the company’s commitment to advancing its enterprise technology strategy.
In his role, Davé will focus on reimagining and executing BioMarin’s technology initiatives, data science, and digital transformation efforts. His leadership is expected to create significant value for patients, employees, and shareholders, as stated by the San Rafael, California-based company.
With over 20 years of experience in information technology and artificial intelligence (AI) within the biopharmaceutical sector, Davé is recognized as a proven leader. His career has been marked by a strong track record of driving patient-centered organizations toward measurable business growth and profitability.
Before joining BioMarin, Davé served as a technology executive at Amgen, Inc. for the past seven and a half years. In his most recent roles there, he led teams focused on digital transformation through AI and innovative digital technologies, positioning the company to remain competitive in an evolving landscape.
Davé’s previous experience includes leadership roles at Bristol Myers Squibb and Merck, where he concentrated on CIO leadership, data science, and research and development.
He holds a Master of Science in Industrial Engineering from the University of Texas and a Bachelor of Science in Mechanical Engineering from Sardar Patel University in Gujarat, India.
“Arpit is a visionary thinker and talented leader who brings to this role a deep understanding of the biopharmaceutical industry and a track record of using technology and AI to deliver for patients and the business,” said Alexander Hardy, President and Chief Executive Officer of BioMarin.
Hardy emphasized that Davé will be responsible for building a strategic vision and roadmap, deploying technologies that will enhance and differentiate BioMarin’s operations across various sectors, including research and development, manufacturing, and commercial organizations.
Expressing his enthusiasm for the new role, Davé stated, “I have long admired BioMarin’s dedication to people living with rare diseases, and I am excited to work as part of this team to create undeniable value for patients, employees, and shareholders.”
He further added, “I am honored to join BioMarin at this pivotal moment where the convergence of biology, data, and AI offers unprecedented potential; my focus will be on empowering our world-class teams and driving innovation to translate these capabilities into faster insights and the accelerated delivery of life-changing therapies to the patients who depend on us.”
Founded in 1997, BioMarin has established a strong reputation for innovation, boasting eight commercial therapies and a robust clinical and preclinical pipeline, according to the company’s release.
This strategic appointment reflects BioMarin’s ongoing commitment to leveraging technology and data to enhance its operations and improve patient outcomes.
According to The American Bazaar, Davé’s leadership is expected to play a crucial role in the company’s future endeavors.